These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 8642041)

  • 1. Lessons from the p53 mutant mouse.
    Jacks T
    J Cancer Res Clin Oncol; 1996; 122(6):319-27. PubMed ID: 8642041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The p53-deficient mouse: a model for basic and applied cancer studies.
    Donehower LA
    Semin Cancer Biol; 1996 Oct; 7(5):269-78. PubMed ID: 9110404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mouse genetics in the 21st century: using gene targeting to create a cornucopia of mouse mutants possessing precise genetic modifications.
    Wilder PJ; Rizzino A
    Cytotechnology; 1993; 11(2):79-99. PubMed ID: 7763692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of p53 transgenic mice in the development of cancer models for multiple purposes.
    Lubet RA; Zhang Z; Wiseman RW; You M
    Exp Lung Res; 2000 Dec; 26(8):581-93. PubMed ID: 11195457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse models with modified p53 sequences to study cancer and ageing.
    Clarke AR; Hollstein M
    Cell Death Differ; 2003 Apr; 10(4):443-50. PubMed ID: 12719721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probing p53 biological functions through the use of genetically engineered mouse models.
    Attardi LD; Donehower LA
    Mutat Res; 2005 Aug; 576(1-2):4-21. PubMed ID: 16038709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse models for generating P53 gene mutation spectra.
    Zielinski B; Liu Z; Hollstein M; Hergenhahn M; Luo JL
    Toxicol Lett; 2002 Aug; 134(1-3):31-7. PubMed ID: 12191858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into aging obtained from p53 mutant mouse models.
    Dumble M; Gatza C; Tyner S; Venkatachalam S; Donehower LA
    Ann N Y Acad Sci; 2004 Jun; 1019():171-7. PubMed ID: 15247009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Establishment of mouse p53 yeast functional assay and evaluation of its detectability of p53 gene mutation].
    Tsunematsu I
    Hokkaido Igaku Zasshi; 1999 Jul; 74(4):301-14. PubMed ID: 10480037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin.
    Zhang Z; Liu Q; Lantry LE; Wang Y; Kelloff GJ; Anderson MW; Wiseman RW; Lubet RA; You M
    Cancer Res; 2000 Feb; 60(4):901-7. PubMed ID: 10706103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early mouse development: lessons from gene targeting.
    St-Jacques B; McMahon AP
    Curr Opin Genet Dev; 1996 Aug; 6(4):439-44. PubMed ID: 8791525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice.
    Ghebranious N; Sell S
    Hepatology; 1998 Apr; 27(4):967-73. PubMed ID: 9537435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse Homolog of the Human
    Park JH; Li J; Starost MF; Liu C; Zhuang J; Chen J; Achatz MI; Kang JG; Wang PY; Savage SA; Hwang PM
    Cancer Res; 2018 Sep; 78(18):5375-5383. PubMed ID: 30042151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke.
    De Flora S; Balansky RM; D'Agostini F; Izzotti A; Camoirano A; Bennicelli C; Zhang Z; Wang Y; Lubet RA; You M
    Cancer Res; 2003 Feb; 63(4):793-800. PubMed ID: 12591728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung-specific expression in mice of a dominant negative mutant form of the p53 tumor suppressor protein.
    Morris GF; Hoyle GW; Athas GB; Lei WH; Xu J; Morris CB; Friedman M
    J La State Med Soc; 1998 Apr; 150(4):179-85. PubMed ID: 9610073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.
    Jonkers J; Meuwissen R; van der Gulden H; Peterse H; van der Valk M; Berns A
    Nat Genet; 2001 Dec; 29(4):418-25. PubMed ID: 11694875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer?
    Blackburn AC; Jerry DJ
    Breast Cancer Res; 2002; 4(3):101-11. PubMed ID: 12052252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse models incorporating alterations in the major tumor suppressor genes P53 and P16: their use in screening for potential carcinogens, developing further relevant mouse models, and screening for potential chemopreventive and chemotherapetutic agents.
    Lubet R; Wang Y; Zhang Z; You M
    Exp Lung Res; 2005; 31(1):117-33. PubMed ID: 15765922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation.
    Hakem R; de la Pompa JL; Elia A; Potter J; Mak TW
    Nat Genet; 1997 Jul; 16(3):298-302. PubMed ID: 9207798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Murine models of neoplasia: functional analysis of the tumour suppressor genes Rb-1 and p53.
    Clarke AR
    Cancer Metastasis Rev; 1995 Jun; 14(2):125-48. PubMed ID: 7554030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.